50 results about "Restenosis" patented technology

The invention relates to the technical field of biomedical materials, in particular to a double-network structure artificial blood vessel with anticoagulation, endothelium promotion and anti-infection functions and a preparation method of the double-network structure artificial blood vessel. The artificial blood vessel comprises a polymer fiber network artificial blood vessel substrate, a microscopic network hydrogel layer penetrating through the polymer fiber network artificial blood vessel substrate, and magnesium-copper alloy particles doped in the hydrogel layer. According to the artificial blood vessel with the double-network structure, the problem that a traditional small-caliber artificial blood vessel is insufficient in mechanical performance is greatly solved, copper ions and magnesium ions are released to the surrounding environment by means of degradation of the magnesium-copper alloy particles in the using process, the microenvironment of the surrounding tissue is adjusted to be alkalescent, nitric oxide is catalytically released, and the mechanical performance of the artificial blood vessel is improved. The artificial blood vessel with the double-network structure is endowed with anticoagulation, endothelium promotion and anti-infection functions. The problems of restenosis and insufficient endothelialization of a small-caliber artificial blood vessel in the prior art are comprehensively solved, and the long-term patency rate of the artificial blood vessel is increased.

A prosthetic heart valve for the treatment of structural heart disease wherein the prosthetic heart valve includes an expandable frame that a) has an open cell geometry in the frame of the prosthetic heart valve that can be used to reduce delivery system size, b) has high radial strength, c) has improved restoration of the physiologic EOA, d) has lower recoil, e) has little or no longitudinal foreshortening, f) allows for proper placement of the bioprosthetic valve in relation to the native commissures of the valve, h) has symmetrical and cylindrical expansion of the prosthetic valve resulting in lower rates of leaflet thrombosis and structural valve deterioration, and / or i) prevents allergic response and restenosis associated with nickel content.

The invention belongs to the technical field of molecular biology diagnosis and treatment, and relates to application of a reagent for detecting or inhibiting FN1 and a product for diagnosing or preventing and treating vascular restenosis. The expression level of the FN1 in a vascular restenosis sample is remarkably increased, and the FN1 can promote phenotypic transformation of vascular smooth muscle cells (VSMC). Meanwhile, further research proves that the FN1 has better diagnosis efficiency on the diagnosis of the vascular restenosis, and is higher in sensitivity, specificity and accuracy, so that the FN1 can be used for effectively diagnosing the vascular restenosis. In addition, in-vivo experiments prove that VSMC phenotypic transformation can be inhibited and vascular restenosis can be improved by inhibiting FN1 expression. The invention provides a new direction for research and development of vascular restenosis related diagnosis and prevention and treatment products, and has a good clinical application prospect.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present application relates to the technical field of vascular interventional treatment instruments, and discloses a system and method for the selective laser ablation of restenosis after the treatment of Budd-Chiari syndrome, comprising a controller, a pulse emission module and a reference element built into a catheter, the system is based on the reference element for periodic self-calibration, collects and processes the associated photoacoustic signals to identify the tissue type, and then realizes the selective ablation of the diseased tissue and the boundary self-stop when the healthy tissue is touched. The present application converts the traditional open-loop energy delivery into a closed-loop self-control process with real-time information interaction capability, so that the ablation operation end can in-situ perceive the tissue boundary and realize autonomous stop, thereby avoiding the problem of damaging the healthy tissue due to uncontrollable energy application, improving the safety of the operation, and having the advantages of high precision, few complications, repeatable treatment and the like.

The invention relates to the technical field of vascular interventional therapy instruments, and discloses an excimer laser ablation system and method for restenosis after Budd-Chiari syndrome interventional therapy, the excimer laser ablation system comprises a controller, a pulse transmitting module and a reference element arranged in a catheter, and the system performs periodic self-calibration based on the reference element; according to the method, associated photoacoustic signals are collected and processed to identify tissue types, selective ablation of lesion tissues and boundary self-stop when healthy tissues are touched are further achieved, traditional open-loop energy delivery is converted into a closed-loop self-control process with real-time information interaction capacity, and the method has the advantages of being simple in structure, convenient to operate and high in practicability. The ablation operation tail end can sense the tissue boundary in situ and achieve automatic stopping, so that the problem that healthy tissue is damaged due to uncontrollable energy application is solved, the safety of an operation is improved, and the advantages of being high in precision, few in complication, capable of achieving repeated treatment and the like are achieved.

The invention relates to a method and device for predicting the risk of restenosis after intravascular treatment of a TARAS patient, a storage medium and a program product. The method comprises the following steps: acquiring target preoperative clinical data and target iconography characteristics collected for a detection object; calculating a risk score based on the target preoperative clinical data and the target iconography features; the risk score is compared with a first threshold value, an auxiliary prediction result of the detection object is determined according to a comparison result, and the auxiliary prediction result is used for representing the restenosis risk of the detection object. The invention aims to provide a model for evaluating the post-PTA restenosis risk of a severe TARAS patient by using anatomical risk factors and other clinical risk factors, so that the risk of an intravascular treatment technology can be quantified, and the clinical popularization and application of the intravascular treatment technology can be promoted.

The invention discloses a zinc alloy stent as well as a preparation method and application thereof. The zinc alloy bracket comprises a zinc-based alloy matrix and a coating arranged on the zinc-based alloy matrix, the coating comprises a zinc layer and a poly-racemic lactic acid coating containing an active drug. According to the zinc alloy stent, the pure zinc layer and the poly-racemic lactic acid coating containing the active medicine are arranged on the zinc-based alloy matrix, so that the early-stage degradation speed of an early-stage zinc alloy implant is slowed down, the number of degradation products is controlled, stimulation of the degradation products to blood vessels is reduced, the probability of occurrence of thrombosis and restenosis in the early-stage and middle-stage is reduced, and the stent has a good application prospect. And the early mechanical property and biocompatibility of the instrument are ensured.

The present application provides a kind of vascular stenosis treatment device, it includes treatment component, the treatment component includes: balloon, the wall of the balloon has a plurality of first holes for liquid to pass, the balloon has unexpanded state and expanded state;Cover, the cover is covered outside the balloon and expands along with the balloon expansion, the cover has a plurality of second holes, when the balloon is in the expanded state, the aperture of the first hole is less than the aperture of the second hole.The vascular stenosis treatment device of the present application can realize accurate positioning, and the cover has a limiting effect on the liquid, so that the drug can be more uniformly and effectively act on the required position of the blood vessel wall, thereby improving the utilization rate of the drug, reducing the incidence of vascular restenosis, and improving the treatment effect.

The utility model provides a cutting woven covered stent, which relates to the technical field of medical instruments, and comprises a cutting skeleton, a woven mesh and an ePTFE membrane, the cutting skeleton is designed by combining an open loop and a closed loop, and the two ends of the stent have a good anchoring effect in vivo; and the middle part is of an open-loop structure, and through the support of the woven mesh, the whole body has good support performance and also has flexibility. The stent composed of the cutting framework, the woven mesh and the ePTFE membrane is arranged, the cutting framework is designed by combining an open loop and a closed loop, and the two ends of the stent have a good anchoring effect in the body; and the middle part is of an open-loop structure, and through the support of the woven mesh, the whole body not only has good support performance, but also has flexibility. The outer layer is coated with the ePTFE membrane, so that the coverage area on plaques is larger, the probability that the plaques fall off from stent meshes can be effectively reduced, and micro-embolism after the plaques fall off is prevented. The ePTFE membranes on the inner layer and the outer layer are dip-coated with the drug-loaded coatings, proliferation of vascular smooth muscles is inhibited, and intravascular restenosis is prevented.

The invention discloses an endovascular interventional targeted drug delivery system for treating pulmonary artery stenosis, and belongs to the technical field of minimally invasive interventional therapy. Compared with the prior art, the intravascular targeted drug delivery system balloon dilatation catheter provided by the invention can be used for interventional therapy of chronic thrombotic pulmonary hypertension (CTEPH). The endovascular intervention targeted drug delivery system for treating pulmonary artery stenosis, provided by the invention, adapts to a pulmonary artery anatomical path, and ensures the pushing property and flexibility in a complex delivery process. Anti-proliferation (such as paclitaxel and derivatives thereof or rapamycin and derivatives thereof) and anticoagulant drugs (such as heparin and tirofiban hydrochloride) are loaded on the surface of the balloon, mechanical expansion and local targeted drug delivery are achieved, and restenosis and thrombosis are inhibited.

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.

The invention discloses a targeted drug release type cardiovascular stent system for preventing vascular restenosis, and belongs to the technical field of interventional medical instruments. Comprising a stent skeleton matched with a coronary artery lumen, a micro-fluidic drug storage bin assembly integrally embedded in the stent skeleton, an intelligent driving assembly correspondingly assembled in a micro-fluidic channel and a targeted release mechanism arranged in the stent skeleton, the micro-fluidic drug storage bin assembly comprises a plurality of independently sealed drug storage bins and corresponding micro-fluidic channels, and the intelligent driving assembly achieves sequential unlocking according to the vascular repair stage through a Venturi tube, a body temperature response type diameter adjusting piece, a sequential degradation sealing piece and an elastic self-reset blocking sealing piece, dynamically adjusts the drug release amount along with the body temperature gradient, and achieves the purpose of repairing the blood vessel. And the liquid medicine is directionally released to a diseased region through the array microtube. The full-period staged precise drug delivery can be realized, the unbalance and unexpected release of the drug are avoided, and the effect and clinical reliability of the stent for preventing the vascular restenosis are improved.

This invention discloses a 3D-printed helical biodegradable anti-inflammatory vascular stent and its preparation method, belonging to the field of vascular stents. The invention uses multiple helical support wires arranged into a tubular shape, with the ends connected in a serpentine transitional manner. The helical support wires are connected by connecting ribs, and the surface is coated. This invention is biodegradable after use, avoiding the harm caused by permanent retention in the body, and has a lower restenosis rate compared to metal stents. The surface of the vascular stent is coated with a spermidine-containing coating to prevent immune rejection of the implanted vascular stent, thereby addressing the problems of inflammation and intimal hyperplasia. The helical structure facilitates contraction and expansion, has good bending flexibility, and the added connecting ribs increase the radial support performance of the vascular stent, better achieving the effect of vascular remodeling. This invention has significant implications in terms of biodegradability, anti-immune rejection, and mechanical properties, and can be used for treatment in different locations such as peripheral and coronary vessels.

The application provides a multifunctional intestinal stent and a preparation method thereof. The multifunctional intestinal stent comprises, from outside to inside, an anti-tumor layer, a load-bearing layer and an anti-stenosis layer. The anti-tumor layer comprises an outer layer and an inner layer, wherein the outer layer is a nanofiber membrane containing MXene, and the inner layer is a composite membrane containing a chemotherapeutic drug, and the inner layer is in contact with the outer side of the load-bearing layer. The load-bearing layer is a tubular stent obtained by 4D printing of a shape memory polymer material. The anti-stenosis layer contains triprolidine. The multifunctional intestinal stent provided by the application can not only rapidly and continuously treat intestinal obstruction caused by space-occupying tumors, but also facilitate coordinated deformation, reduce tissue abrasion, and has an anti-restenosis function, so as to better maintain normal intestinal function.

The application discloses a kind of film-covered stent and its preparation method in the technical field of medical devices, including polymer film tube, metal stent and polymer fixing belt;The outer circumferential surface of the polymer film tube is provided with annular or spiral wave-shaped groove along the axial direction, the groove is formed by heat pressing on the surface of the polymer film tube according to the self-defined path, the metal stent is wave-shaped woven structure with wave crest and wave trough structure, and the inner diameter size of the metal stent in the natural expansion state is between the inner diameter and the outer diameter of the polymer film tube;The metal stent is at least partially embedded in the groove to realize the pre-fixing of the two;The polymer fixing belt is annular or spiral band structure and is wrapped around the outside of the polymer film tube, part of its inner wall is in contact with the outer surface of the metal stent, and the other part covers and contacts the outer surface of the polymer film tube.The application reduces the risk of stent and film tube separation and the risk of postoperative restenosis, and improves the use safety of the film-covered stent.

The application discloses an intracranial laser balloon dilatation catheter and an operation method thereof. The intracranial laser balloon dilatation catheter comprises a tube body, the tube body comprises an inner tube and an outer tube which are nested inside and outside, an elastic piece is welded at the distal end of the inner tube, the inner tube and the outer tube of the distal end tube body have a first radial gap, the inner tube and the outer tube of the proximal end tube body have a second radial gap, the first radial gap is smaller than the second radial gap, a balloon body, an optical fiber, a movable piece which is located in the radial gap of the inner tube and the outer tube and has a first position with at least a part located in the first radial gap and a second position with all located in the second radial gap, a control piece which controls the movable piece to switch from the first position to the second position, and a laser generating module which emits laser with a wavelength of 400-750 nm and a repair function. The intracranial laser balloon dilatation catheter can avoid intravascular restenosis, the flow rate is slow when the balloon body is inflated, the flow rate is fast when the fluid in the balloon body is released, and the safety and convenience of the operation are considered.

The invention discloses a coronary medicine balloon dilatation catheter, and belongs to the technical field of medical instruments. In order to solve the problems that an existing drug balloon is high in blood flow blocking risk, large in drug loss and uneven in drug distribution, the balloon dilatation catheter comprises a catheter body, a dilatation balloon, a drug delivery catheter, a drug storage bin, a driving connecting rod, a connecting ring and a guiding head. The dosing catheter protrudes out of the periphery of the dilatation balloon at intervals, the flexible side wall of the medicine storage bin communicates with the liquid injection cavity channel, and the driving connecting rod drives the dosing catheter to rotationally apply medicine through spiral transmission; the catheter body is provided with an independent blood flow cavity channel and a blood inlet, and a gap formed by the catheter body and the administration catheter forms a double-channel blood flow path. The invention realizes the synergy of vasodilatation, accurate and uniform administration and continuous blood perfusion, reduces drug loss and non-targeted deposition, reduces myocardial ischemia complications and postoperative restenosis risk, is simple and convenient to operate, and is suitable for various coronary heart disease treatment scenes.

Atherectomy-angioplasty devices, systems, and methods reduce the device costs, procedure times, and risks associated with clinician error and patient trauma that accompany separate atherectomy and angioplasty devices. An example atherectomy-angioplasty device includes a tubular body, an elongate rotor, a plaque-debulking element, and an elongate balloon. The tubular body includes a rotor lumen and an inflation lumen. The elongate rotor is disposed in the rotor lumen. The plaque-debulking element is configured to debulk atherosclerotic or restenotic plaques in a blood-vessel lumen of a patient. To do so, the plaque-debulking element is actuated by the elongate rotor when the elongate rotor is rotated around its longitudinal axis in the rotor lumen. The elongate balloon is over a distal portion of the tubular body. The elongate balloon is fluidly connected to the inflation lumen for inflating or deflating the elongate balloon, as desired, for preventing dispersion of atherosclerotic debris, angioplasty, or both.

The present invention relates a process for preparing a compound of Formula XX wherein: R1 is hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is an N-containign heterocyclyl or heteroaryl; and Q is optionally substitued aryl or heteroaryl. Furthermore a compound of the present invention are useful in the treamtment of various inflammatory, autoimmune and allergic diseases, such as method of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoartluitis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the overexpression and over-activation of a matrix metalloproteinase using the compound.

This invention relates to a drug delivery method for a membrane-covered stent, comprising the following steps: 1) preparing a coating solution and atomizing it; 2) applying a drug coating to the stent and drying it; 3) covering the stent surface with a thin film; 4) preparing a coating solution, atomizing the membrane-covered stent, and applying the coating solution to the surface of the membrane-covered stent; 5) atomizing the membrane-covered stent with a solvent and drying it. The beneficial effects of this invention are that the design of the inner and outer drug coatings on the stent and the membrane surface can flexibly achieve multifunctional composite effects according to different drug delivery purposes, drug delivery sites, and drug delivery methods, and the inner and outer drug coatings do not affect each other, with controllable drug release rates, achieving the purpose of preventing restenosis and reducing thrombus formation.

The utility model discloses a threaded balloon and a balloon catheter, and relates to the technical field of medical instruments, in particular to a threaded balloon and a balloon catheter, which comprise a balloon and a fixed catheter, the balloon is fixedly sleeved on the surface of the fixed catheter, an expansion component is arranged on the surface of a balloon body corresponding to the balloon, and one end of the fixed catheter is fixedly connected with a connecting ring. A balloon filling opening is formed in the surface of the connecting ring; through the arrangement of a balloon, an expansion assembly, a liquid medicine conveying pipe and a liquid medicine spraying assembly, after the device reaches the lesion position of a patient, the balloon is filled through a balloon filling opening, so that the expansion assembly is supported and embedded in the lesion position of the patient; the liquid medicine conveying pipe is used for conveying the liquid medicine to the liquid medicine spraying assembly and treating the lesion part of the patient, so that the lesion part of the patient is effectively subjected to medicine treatment, the restenosis after the vascular intervention operation of the patient is effectively prevented, and the practicability and applicability of the device are effectively improved.

The application discloses an intracranial laser balloon dilatation catheter, which comprises a tube body, a balloon body and a laser generating module. The tube body is provided with a fluid channel and an optical fiber channel. The balloon body is located at the outer periphery of the distal end of the tube body and is in communication with the fluid channel. The optical fiber is arranged in the optical fiber channel and has a light-emitting section extending to the position of the balloon body. The elastic member is arranged at the distal end of the inner tube. The diameter of the elastic member gradually increases from the distal end to the proximal end of the elastic member. The laser generating module is connected to the proximal end of the optical fiber. The laser generating module emits laser with a repairing function. The intracranial laser balloon dilatation catheter can avoid intravascular restenosis and ensure the safety and convenience of the operation.

The utility model belongs to the technical field of medical instruments, and discloses a ureteral stent. The ureteral stent comprises a metal framework, the metal framework is of a spiral spring structure, an elastic thin film is partially or completely attached to the inner side and / or the outer side of the metal framework, the thin film is formed by covering a film when the spiral spring structure is pulled open to generate a gap, and when the spiral spring structure is released and restored to a natural state, the elastic thin film is attached to the metal framework. The thin film is extruded by the rebounded spiral spring structure, and the thin film and the metal framework are encircled to form an impermeable tube cavity. Due to the fact that the elastic thin film is attached to the inner side and / or the outer side of the metal framework, when the metal framework is stretched or compressed, complete impermeability can be kept, no gap is generated at the bending gap of the ureteral stent, ureteral wall tissue proliferative ingrowth is avoided, restenosis of the ureter is effectively avoided, and the ureteral stent has the advantages of being simple in structure and convenient to use. The clinical experience of the patient is greatly improved, and the pain is relieved.

A compound of Formula (I) is provided: (I) Salts and crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, inflammatory and fibrotic diseases, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

The invention relates to the field of medical instruments, in particular to a nano diamond-like film intravascular stent and a preparation method thereof.The preparation method comprises the following steps that firstly, a base material is pretreated, then the nano diamond-like film stent is prepared through a plasma enhanced chemical vapor deposition technology, and after an equipment reaction chamber is adjusted to be in a vacuum state, the nano diamond-like film intravascular stent is prepared under argon protection; the method comprises the following steps: inputting benzene into a vacuum reaction chamber of direct-current arc discharge plasma, introducing silane gas at the same time, bombarding the generated plasma to a negative voltage cathode, and forming a diamond-like carbon film containing a silicon element on the surface when the plasma passes through a substrate material support sample, the silicon element content in the diamond-like carbon film being 15-45%; the silicon element is mainly added to form the elastic concentration gradient type diamond-like carbon film stent, so that the adhesive force, toughness, tensile strength and other physical properties of the coating are improved, the stent has good biocompatibility, and later thrombosis and restenosis after stent implantation are avoided.

The invention provides functional hydrogel with a cell energy metabolism regulation function as well as a preparation method and application of the functional hydrogel, and belongs to the technical field of tissue engineering and vascular implants. Mitochondria and epigallocatechin gallate are stably loaded in methacrylic acid modified hyaluronic acid hydrogel, and surface plasma activation and UV photo-crosslinking technologies are combined, so that firm combination of a coating and the surface of a stent, efficient fixation and slow release of mitochondria and multi-target vascular repair promotion are realized. The technology not only can effectively promote vascular endothelialization, but also can inhibit abnormal proliferation and inflammatory response of smooth muscle cells and remarkably reduce the occurrence rate of restenosis, overcomes the defects of the prior art in the aspects of stability, functionality and sustainability, and has important clinical application value and industrialization prospect.

The invention relates to an internal arteriovenous fistula stent which comprises a base stent used for covering an arteriovenous anastomotic stoma area and a hybrid stent used for being arranged outside a to-be-anastomosed vein in a sleeving mode, the hybrid stent is of a net-shaped structure formed by composite weaving of degradable metal wires and non-degradable metal wires, the temporary supporting function of degradable materials is utilized, and the function of the hybrid stent is achieved. And a durable flexible framework is constructed by relying on non-degradable wires. The internal arteriovenous fistula stent can provide necessary constraint for blood vessels, especially anastomotic stoma areas in the early stage of a surgery so as to inhibit excessive expansion and intimal hyperplasia caused by abnormal stress, the degradable metal wires are gradually degraded along with gradual completion of vein artery remodeling, the stent can still maintain a complete net-shaped structure, and the stent has the advantages of being simple in structure and convenient to use. Meanwhile, the restraining effect can be gradually reduced, rigid restraining is avoided, and therefore the possibility that the stent structure loses efficacy and the blood vessel is restenosis is greatly reduced while the smoothness of the blood vessel is protected.

A prosthetic heart valve is disclosed for use in the treatment of structural heart diseases wherein the prosthetic heart valve comprises an expandable frame formed from a rhenium-containing metal alloy. The novel geometry of the expandable frame, in combination with the frame formed partially or entirely from the rhenium-containing alloy, enables the formation of a frame that: a) has an open mesh geometry in the frame of the prosthetic heart valve, which can be used to reduce delivery system size, and a) has an open mesh geometry in the frame of the prosthetic heart valve, which can be used to reduce delivery system size; the present invention relates to a bioprosthetic valve, b) with high radial strength, c) with improved recovery of physiological EGA, d) with lower backlash, e) without perspective shortening, f) allowing proper placement of the bioprosthetic valve relative to the natural junction of the valve, h) with symmetric and cylindrical expansion of the prosthetic valve, thereby reducing the incidence of leaflet thrombosis and structural valve deterioration, and to a method for manufacturing the same. And i) prevent anaphylaxis and restenosis associated with the nickel content.

The invention relates to the technical field of biomedicine, in particular to application of a gene inhibitor in preparation of a medicine for preventing or treating restenosis after vascular injury. Specific knockdown or knockout of TRIM65 or MYH9 can inhibit formation of neointima, excessive intima neogenesis is the core pathological feature of restenosis after vascular injury, and therefore the TRIM65 inhibitor or MYH9 inhibitor can be used for preparing the medicine for preventing or treating restenosis after vascular injury.